Article Sidebar
Published:
Jan 20, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Clinical effectiveness of a combination of metformin and ipragliflozin in the management of patients with type-2 diabetes mellitus
Abstract
Purpose: To investigate the clinical effectiveness of combination of metformin and ipragliflozin in the treatment of patients with type-2 diabetes mellitus (T2DM).
Methods: Patients with T2DM (n = 100) aged 35 – 68 years (mean age = 51.5 ± 16.5 years) were recruited over a 1-year period and randomly assigned to 2 groups (50 patients/group): control and study groups. Control group patients were treated with metformin orally at a dose of 500 mg/kg body weight twice a day, while patients in the study group received 50 mg ipragliflozin/kg, orally once a day, in addition to metformin. Fasting blood glucose (FBG), 2-h postprandial blood glucose (PBG), bedtime glucose (BBG) and glycated hemoglobin (HbAlc) concentrations were measured in patients’ plasma before and after treatment. Incidence of adverse reactions, changes in body fat and clinical effectiveness were also determined.
Results: FBG, 2-h PBG, BBG, HbAlc, body fat and incidence of adverse reactions were markedly reduced in T2DM patients treated with the combination of metformin and ipragliflozin, relative to those treated with metformin alone (p < 0.05). After treatment, the proportion of outcomes categorized as ‘markedly effective’ and ‘total effectiveness’ was higher in the study group than in the control group (p < 0.05).
Conclusion: The combination of metformin and ipragliflozin is safer and more clinically effective in the treatment of T2DM than metformin monotherapy.
